EANS-News: SYGNIS Pharma AG SYGNIS announces the adaptation of its
organisation to the new business activity
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Strategic management decisions
Heidelberg (euro adhoc) - Press Release
SYGNIS announces the adaptation of its organisation to the new business activity
Heidelberg 20 December 2012 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) announced today the discontinuation of its
therapeutic R&D project KIBRA and the adaptation of its organisation to the new
business activity. At the Heidelberg site the staff will be reduced by 10
employees. These measures are implemented to concentrate the financial resources
on the development and marketing of novel technologies in molecular biology in
line with the new corporate strategy. This new business was acquired in 2012 by
joining forces with the Spanish X-Pol Biotech.
Peter Willinger, Chief Financial Officer, stated: "Despite good progress in the
project, an outlicensing of the KIBRA project was unfortunately not possible
within the available timeline. The KIBRA project can not be continued with
internal resources. The realignment of the company regrettably makes a staff
reduction necessary. I would like to extend my sincere gratitude to all
employees affected for their excellent work for SYGNIS."
For further information please contact:
SYGNIS Pharma AG
Peter Willinger
CFO
SYGNIS Pharma AG
Tel.: +49 6221 454 836
E-mail: peter.willinger@sygnis.de
About SYGNIS Pharma AG: www.sygnis.de
SYGNIS Pharma AG (Heidelberg, Germany) is a biotech company listed in the Prime
Standard of the German Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).
According to the 2012 newly defined business strategy, the company focuses on
the development and marketing of novel technologies in molecular biology, e.g.
in the field of DNA amplification and sequencing. For the key product
"Qualiphi®", an improved polymerase for amplifying DNA, an exclusive worldwide
license has been granted to Qiagen in July 2012.
### Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly predictions of
future results, trends, plans or goals. These statements should not be
considered to be total guarantees since given their very nature they are subject
to known and unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or implied
predictions contained in such statements. SYGNIS does not undertake to publicly
update or revise these statements in the light of new information or future
results or for any other reason. ###
Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1RFM03
indexes:
stockmarkets:
language: English